)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Pulmonx
Pulmonx (LUNG) investor relations material
Pulmonx Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary27 Oct, 2026
Executive summary
Q3 revenue rose 6.2% YoY to $22.835M as Zephyr Valve procedure volumes grew; operating expenses and net loss declined, supporting improved operating leverage.
9M revenue fell 2.5% YoY to $66.177M, while net loss narrowed to $32.128M from $43.578M.
FY 2026 revenue guidance was reiterated at $90M–$92M.
Financial highlights
Q3 revenue was $22.835M vs. $21.502M; gross profit was $17.399M vs. $16.052M.
Q3 operating expenses fell 18.2% YoY to $24.889M, including SG&A of $20.0M, down 21.8%, and R&D of $4.9M, up 0.4%.
Q3 operating loss was $7.490M vs. $14.393M; net loss was $8.394M vs. $13.957M, and diluted EPS was $(0.19) vs. $(0.34).
Adjusted EBITDA loss was $3.528M vs. $8.223M, a 57% YoY reduction.
9M revenue was $66.177M vs. $67.899M; operating expenses fell 13.6% to $80.7M and gross profit rose to $51.2M from $49.6M.
Outlook and guidance
FY 2026 revenue guidance remains $90M–$92M; gross margin is expected to be ~77%.
FY 2026 operating expenses are expected at $108M–$109M, including ~ $14M of non-cash stock-based compensation.
Cash, cash equivalents and marketable securities are expected to decrease by ~ $22M in FY 2026, assuming no additional credit-facility drawdowns.
Guidance contemplates China shipments resuming in Q4 or early 2027; distributor shipments are anticipated by early 2027.
Management expects losses for the next several years and substantial additional funding needs; current cash is expected to fund planned operations for at least 12 months after interim financial-statement issuance.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Pulmonx
- Record Q4 revenue and strong U.S. growth underpin FY 2024 revenue guidance of $81M–$84M.LUNG
Q4 2023 - Zephyr Valves pair RCT-backed treatment with a stated $12B market opportunity.LUNGInvestor presentation
- AeriSeal to expand market by 20% next year as cost controls and growth initiatives take hold.LUNGCanaccord Genuity's 46th Annual Growth Conference
- Q2 2026 revenue was $22.8M, net loss improved, and gross margin hit 78%.LUNGQ2 2026
- Strong growth, clinical progress, and workflow innovation set the stage for global expansion.LUNG2024 Wells Fargo Healthcare Conference
- 2026 guidance targets $90–92M revenue, improved margins, and lower cash burn after a transitional 2025.LUNGQ4 2025
- Q2 revenue hit $20.8M, up 21% year-over-year, with improved margins and narrowed net loss.LUNGQ2 2024
- Q1 revenue rose 20% to $22.5M, with strong international growth and reaffirmed guidance.LUNGQ1 2025
- 2024 revenue rose 22% to $83.8M, with 2025 guidance for 15–18% growth and stable margins.LUNGQ4 2024
Next Pulmonx earnings date
Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum11 Nov, 2026
Pulmonx
Next Pulmonx earnings date
Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum11 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company markets airway clearance therapy systems used to administer medications and mucus-thinning agents to treat cystic fibrosis and other respiratory conditions. Its products include Pulmonx System for Lungs, Lung Flute device, and Combyn device that are used in the subglottic suctioning of mucus from the upper part of the lungs. Pulmonx Corporation was founded in 1995 and is headquartered in Redwood City, California.